NCT00502905View on ClinicalTrials.gov

Busulfan and Fludarabine in Patients With AML and MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Leukemia
Interventions
DRUG

Busulfan

130 mg/m\^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.

DRUG

Fludarabine

40 mg/m\^2 through a central venous catheter over one hour, once a day, for four days.

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00502905 - Busulfan and Fludarabine in Patients With AML and MDS | Biotech Hunter | Biotech Hunter